Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma

4 Oct 2017

Abstract excerpt

Purpose Enhancer of zeste homolog 2 (EZH2), a chromatin remodeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC). However, the effect of EZH2 on outcomes in localized ccRCC is unclear, and molecular biomarkers are not currently integrated into prognostic models or adjuvant therapy trials. Methods We performed Cox regression to evaluate the association of tumor-based EZH2 gene and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28976794
DOI: 10.1200/jco.2017.73.3238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell CarcinomaPMID 28976794Read ↗

Expression of EZH2 in renal cell carcinoma as a novel prognostic markerSemantic proximity Read ↗

SHOX2-Driven Lymphatic Metastasis in pT1 Non-Clear Cell Renal Cell Carcinoma: A Biomarker-Guided Risk Stratification and Therapeutic StrategySemantic proximity Read ↗

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.Semantic proximity Read ↗

Downregulation of ENPP4 Is Associated with Poor Prognosis and Enhanced Malignant Phenotypes in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

LHX2 is associated with tumor microenvironment characteristics in clear cell renal cell carcinoma and modulates the malignant phenotypes of cancer cells.Semantic proximity Read ↗

A Zic2/Runx2/NOLC1 signaling axis mediates tumor growth and metastasis in clear cell renal cell carcinomaSemantic proximity Read ↗

Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinomaSemantic proximity Read ↗

FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma.Semantic proximity Read ↗

Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.Semantic proximity Read ↗

The value of EYA1/3/4 in Clear Cell Renal Cell Carcinoma: a study from multiple databasesSemantic proximity Read ↗

Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017, based on A SEER DatabaseSemantic proximity Read ↗

VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.